Focus on Adoptive T Cell Transfer Trials in Melanoma
Adoptive Cell Transfer (ACT) of Tumor-Infiltrating Lymphocytes (TIL) in combination with lymphodepletion has proven to be an effective treatment for metastatic melanoma patients, with an objective response rate in 50%–70% of the patients. It is based on the ex vivo expansion and activation of tumor-...
Saved in:
Main Authors: | Liat Hershkovitz, Jacob Schachter, Avraham J. Treves, Michal J. Besser |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2010-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2010/260267 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy
by: R. Ortenberg, et al.
Published: (2015-01-01) -
Application of adoptive cell therapy in malignant melanoma
by: Qianrong Hu, et al.
Published: (2025-01-01) -
CD133+PD-L1+ cancer cells confer resistance to adoptively transferred engineered macrophage-based therapy in melanoma
by: Jiaojiao Xu, et al.
Published: (2025-01-01) -
Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients
by: Mélanie Saint-Jean, et al.
Published: (2018-01-01) -
Ocular Melanoma Metastasizing to Intra-Abdominal Lymph Nodes
by: David Aranovich, et al.
Published: (2013-01-01)